Trump tariffs drive pharma manufacturing to US but risk inflation and disruption
Pressure may grow on companies to repatriate production, raising production costs and potentially medicine prices too.
In Association With 3M
Enabling process intensification in biopharma manufacturing
EU Critical Medicines Act: closer to ending overreliance on Asian manufacturers
Optimising biopharma production through process intensification
Resolving challenges with product recovery in biopharma manufacturing
Overcoming challenges with scalability in biopharma manufacturing
Solving problems with harvest clarification using fibre-based chromatography
